The level of IL-1?, IL-10 and IL-17A in Alzheimer's disease patients: Comparative study

Main Article Content

Alaa A. Hamdan
Alice K. Melconian
Ali H. Adhia
Amir F. Alhaidary

Abstract

The objective of this study is to evaluate the level of cytokines IL-1?, IL-10 and IL-17A in the serum of patients with Alzheimer's disease (AD), vascular dementia (VD) and down syndrome (DS). The results showed that Serum level of IL-1? was significantly increased in AD patients (3.79 ± 0.26 pg/ml) as compared with DS patients (2.78 ± 0.39 pg/ml) or controls (2.78 ± 0.22 pg/ml), while no significant difference was observed between AD and VD (3.25 ± 0.20 pg/ml) patients or between VD patients, DS patients and controls. The serum level of IL-10 was approximated in VD and DS patients and controls (3.39 ± 0.24, 2.77 ± 0.39 and 3.41 ± 0.35 pg/ml, respectively), but was significantly (P ? 0.05) increased in AD patients (5.73 ± 0.55 pg/ml) as compared to these groups. The serum level IL-17A was significantly increased in AD and VD patients (6.28 ± 0.35 and 5.32 ± 0.42 pg/ml, respectively) as compared with DS patients (3.75 ± 0.40 pg/ml) or controls (4.05 ± 0.28 pg/ml).IL-10 is important to diffrentiation between AD and VD.

Article Details

How to Cite
1.
The level of IL-1?, IL-10 and IL-17A in Alzheimer’s disease patients: Comparative study. Baghdad Sci.J [Internet]. 2014 Dec. 7 [cited 2024 Dec. 27];11(4):1486-92. Available from: https://bsj.uobaghdad.edu.iq/index.php/BSJ/article/view/2044
Section
article

How to Cite

1.
The level of IL-1?, IL-10 and IL-17A in Alzheimer’s disease patients: Comparative study. Baghdad Sci.J [Internet]. 2014 Dec. 7 [cited 2024 Dec. 27];11(4):1486-92. Available from: https://bsj.uobaghdad.edu.iq/index.php/BSJ/article/view/2044

Similar Articles

You may also start an advanced similarity search for this article.